Phase 4 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been newly diagnosed with a type of abnormal blood vessel growth (called CNV) in the central part of your eye (the macula), confirmed by specific eye scans, and have not yet received any treatment for it.
• Your vision in the study eye is reduced — roughly between 20/40 and 20/200 on a standard eye chart — and this vision loss is mainly caused by the CNV.
• Your eye scans show a build-up of fluid or swelling in the very centre of the macula in the study eye.
• You are able to read and sign a consent form agreeing to take part in the study.

Who may not be able to join:

• You have had a heart attack or stroke in the last 3 months.
• There is significant bleeding under the retina in the study eye, covering more than 25% of the affected area.
• There is significant scarring or fibrous tissue in the study eye, covering more than 50% of the affected area.
• There is damage to a specific layer of the eye (the RPE) in the very centre of the macula in the study eye.
• The total area affected in the study eye is larger than a certain size limit, as measured by eye scans (confirm with trial site).
• You have poorly controlled glaucoma (high eye pressure) in the study eye that has not responded to glaucoma treatment.
• You have a specific type of eye inflammation (uveitis) caused by the immune system or an unknown cause in the study eye.
• You have other unrelated eye conditions in the macula of the study eye (such as a macular hole or a membrane over the retina) that could affect your vision.
• You have significant cloudiness in the eye (such as a cataract) that could interfere with vision testing or eye scans in the study eye.
• You have diabetic eye disease or any other blood vessel disease of the retina in the study eye.
• You currently have any infection or inflammation around or outside the eye (such as eyelid, cornea, or conjunctiva problems) in either eye at the time of your screening appointment.
• You have had any infection or inflammation inside either eye within the past 12 weeks (84 days) before your screening appointment.
• You are allergic or sensitive to any ingredient in the study drug.
• You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.